Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - MusclePharm Corp | mslp2016kex321.htm |
| EX-31.2 - EXHIBIT 31.2 - MusclePharm Corp | mslp2016kex312.htm |
| EX-31.1 - EXHIBIT 31.1 - MusclePharm Corp | mslp2016kex311.htm |
| EX-21.1 - EXHIBIT 21.1 - MusclePharm Corp | mslp2016kex21.htm |
| EX-10.15 - EXHIBIT 10.15 - MusclePharm Corp | mslp2016kex1015.htm |
| EX-10.14 - EXHIBIT 10.14 - MusclePharm Corp | mslp2016kex1014.htm |
| 10-K - FORM 10-K - MusclePharm Corp | mslp201610k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report of MusclePharm Corporation (the “Company”), on Form 10-K for the year ended December 31, 2016, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Peter C. Lynch, Principal Financial Officer of the Company, certify pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section. 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: March 15, 2017 | By: | /s/ Peter C. Lynch | |
| Peter C. Lynch | |||
| Chief Financial Officer | |||